Evotec (EVT) Given a €17.00 Price Target at Deutsche Bank

Evotec (ETR:EVT) has been given a €17.00 ($20.24) target price by research analysts at Deutsche Bank in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s price objective indicates a potential upside of 46.74% from the company’s previous close.

A number of other analysts have also weighed in on EVT. Berenberg Bank set a €13.00 ($15.48) price objective on shares of Evotec and gave the stock a “neutral” rating in a research note on Thursday, August 10th. Oddo Securities set a €14.00 ($16.67) price objective on shares of Evotec and gave the stock a “neutral” rating in a research note on Friday, August 11th. Finally, Oddo Bhf set a €20.00 ($23.81) price objective on shares of Evotec and gave the stock a “buy” rating in a research note on Thursday, November 9th.

Evotec (ETR:EVT) opened at €11.59 ($13.79) on Tuesday. Evotec has a fifty-two week low of €5.93 ($7.06) and a fifty-two week high of €22.50 ($26.79).

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/05/evotec-evt-given-a-17-00-price-target-at-deutsche-bank.html.

Evotec Company Profile

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.

What are top analysts saying about Evotec AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evotec AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit